BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024

The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as well as an update on monotherapy armcombination data from the Phase …
Jetzt den vollständigen Artikel lesen